| Ms Rosemary Janet Geary, MD | |
|
1100 S Dobson Rd Ste 223, Chandler, AZ 85286-6160 | |
| (480) 821-8888 | |
| (480) 821-0888 |
| Full Name | Ms Rosemary Janet Geary |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 30 Years |
| Location | 1100 S Dobson Rd Ste 223, Chandler, Arizona |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1467431668 | NPI | - | NPPES |
| 412054293 | Other | AZ | TRICARE PROVIDER # |
| 448812 | Medicaid | AZ | |
| 124775 | Other | AZ | HEALTHNET PROVIDER # |
| 5530667013 | Other | AZ | CIGNA PROVIDER # |
| AZ0723550 | Other | AZ | BCBS PROVIDER # |
| Z72153 | Other | AZ | GROUP MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 26816 (Arizona) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| East Valley Dermatology Center | 8022093384 | 15 |
News Archive
Patients with severe cases of kidney stones are 26 percent less likely to receive timely treatment when they're admitted to the hospital on the weekend, according to a study by researchers at Loyola Medicine and Loyola University Chicago Stritch School of Medicine.
Researchers have found that adherence to taking medications improved in people with bipolar disorder with the use of long-term injectable meds combined with psychosocial intervention.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the U.S. Food and Drug Administration (FDA) has accepted the filing of the Company's October 30, 2012 resubmission of its New Drug Application (NDA) for Lymphoseek (Technetium Tc 99m Tilmanocept) Injection.
Researchers at the University of Alabama at Birmingham Comprehensive Diabetes Center have discovered a safe and effective novel therapy to reduce insulin requirements and hypoglycemic episodes in adult subjects with recent onset Type 1 diabetes by promoting the patient's own beta cell function and insulin production - the first such discovery to target diabetes in this manner.
CSL Behring announced today that the first patient has been treated as part of the REPLACE Phase III clinical trial evaluating the efficacy and safety of fibrinogen concentrate (Human) (FCH) in controlling microvascular bleeding during aortic aneurysm surgery.
› Verified 4 days ago
| Entity Name | East Valley Dermatology Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366529836 PECOS PAC ID: 8022093384 Enrollment ID: O20040621001518 |
News Archive
Patients with severe cases of kidney stones are 26 percent less likely to receive timely treatment when they're admitted to the hospital on the weekend, according to a study by researchers at Loyola Medicine and Loyola University Chicago Stritch School of Medicine.
Researchers have found that adherence to taking medications improved in people with bipolar disorder with the use of long-term injectable meds combined with psychosocial intervention.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the U.S. Food and Drug Administration (FDA) has accepted the filing of the Company's October 30, 2012 resubmission of its New Drug Application (NDA) for Lymphoseek (Technetium Tc 99m Tilmanocept) Injection.
Researchers at the University of Alabama at Birmingham Comprehensive Diabetes Center have discovered a safe and effective novel therapy to reduce insulin requirements and hypoglycemic episodes in adult subjects with recent onset Type 1 diabetes by promoting the patient's own beta cell function and insulin production - the first such discovery to target diabetes in this manner.
CSL Behring announced today that the first patient has been treated as part of the REPLACE Phase III clinical trial evaluating the efficacy and safety of fibrinogen concentrate (Human) (FCH) in controlling microvascular bleeding during aortic aneurysm surgery.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Rosemary Janet Geary, MD 1100 S Dobson Rd Ste 223, Chandler, AZ 85286-6160 Ph: (480) 821-8888 | Ms Rosemary Janet Geary, MD 1100 S Dobson Rd Ste 223, Chandler, AZ 85286-6160 Ph: (480) 821-8888 |
News Archive
Patients with severe cases of kidney stones are 26 percent less likely to receive timely treatment when they're admitted to the hospital on the weekend, according to a study by researchers at Loyola Medicine and Loyola University Chicago Stritch School of Medicine.
Researchers have found that adherence to taking medications improved in people with bipolar disorder with the use of long-term injectable meds combined with psychosocial intervention.
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, announced today that the U.S. Food and Drug Administration (FDA) has accepted the filing of the Company's October 30, 2012 resubmission of its New Drug Application (NDA) for Lymphoseek (Technetium Tc 99m Tilmanocept) Injection.
Researchers at the University of Alabama at Birmingham Comprehensive Diabetes Center have discovered a safe and effective novel therapy to reduce insulin requirements and hypoglycemic episodes in adult subjects with recent onset Type 1 diabetes by promoting the patient's own beta cell function and insulin production - the first such discovery to target diabetes in this manner.
CSL Behring announced today that the first patient has been treated as part of the REPLACE Phase III clinical trial evaluating the efficacy and safety of fibrinogen concentrate (Human) (FCH) in controlling microvascular bleeding during aortic aneurysm surgery.
› Verified 4 days ago
Joseph David Allgeier, DO Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3930 S Alma School Rd Ste 8, Chandler, AZ 85248 Phone: 480-917-4815 Fax: 480-963-2654 | |
Jill J Mckenzie, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1100 S Dobson Rd, 223, Chandler, AZ 85286 Phone: 480-821-8888 Fax: 480-821-0888 | |
Burrell Harvey Wolk, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 725 S Dobson Rd, Suite 200, Chandler, AZ 85224 Phone: 480-899-7546 Fax: 480-899-7599 | |
Dr. Ryan Lee Owen, D.O, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 725 S Dobson Rd Ste 200, Chandler, AZ 85224 Phone: 480-899-7546 | |
Dr. Edward Prodanovic, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 725 S Dobson Rd, Chandler, AZ 85224 Phone: 480-899-7546 Fax: 480-899-7599 | |
Dr. Ryan Falsey, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 1100 S Dobson Rd, #223, Chandler, AZ 85286 Phone: 480-821-8888 Fax: 480-821-0888 | |
Susan Rutledge Pardee, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 312 N Alma School Rd Ste 5, Chandler, AZ 85224 Phone: 480-948-8400 Fax: 480-948-8401 |